External Controls: FDA Guidance Provides Clarity But Does Little To Remove Hurdles

Agency discourages use of externally controlled trials in all but a very limited number of situations truly ripe for such an approach; new draft guidance discusses at length the various confounding factors that can introduce bias into a comparison between an investigational treatment and an external control using either real-world data or data from another clinical trial.

Big wall
The road to use of external controls will be blocked for most drug development programs. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards